scholarly journals P10. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T cell and B cell responses but improves clinical efficacy in a murine pancreatic carcinoma model

2014 ◽  
Vol 2 (S2) ◽  
Author(s):  
C Bauer ◽  
A Sterzik ◽  
F Bauernfeind ◽  
P Duewell ◽  
C Conrad ◽  
...  
2014 ◽  
Vol 63 (4) ◽  
pp. 321-333 ◽  
Author(s):  
Christian Bauer ◽  
Alexander Sterzik ◽  
Franz Bauernfeind ◽  
Peter Duewell ◽  
Claudius Conrad ◽  
...  

2011 ◽  
Vol 60 (9) ◽  
Author(s):  
Frank Neumann ◽  
Boris Kubuschok ◽  
Kubilay Ertan ◽  
Claudia Schormann ◽  
Stefan Stevanovic ◽  
...  

2016 ◽  
Vol 1 (4) ◽  
Author(s):  
E. Ashley Moseman ◽  
Tuoqi Wu ◽  
Juan Carlos de la Torre ◽  
Pamela L. Schwartzberg ◽  
Dorian B. McGavern

Author(s):  
Felix G. Delgado ◽  
Karina I. Torres ◽  
Jaime E. Castellanos ◽  
Consuelo Romero-Sánchez ◽  
Etienne Simon-Lorière ◽  
...  

The high level of dengue virus (DENV) seroprevalence in areas where Zika virus (ZIKV) is circulating and the cross-reactivity between these two viruses have raised concerns on the risk of increased ZIKV disease severity for patients with a history of previous DENV infection. To determine the role of DENV pre-immunity in ZIKV infection, we analysed the T and B cell responses against ZIKV in donors with or without previous DENV infection. Using PBMCs from donors living in an endemic area in Colombia, we have identified, by interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay, most of the immunodominant ZIKV T-cell epitopes in the non-structural proteins NS1, NS3 and NS5. Analyses of the T and B-cell responses in the same donors revealed a stronger T-cell response against peptides conserved between DENV and ZIKV, with a higher level of ZIKV-neutralizing antibodies in DENV-immune donors, in comparison with DENV-naïve donors. Strikingly, the potential for antibody mediated enhancement of ZIKV infection was reduced in donors with sequential DENV and ZIKV infection in comparison with donors with DENV infection only. Altogether, these data suggest that individuals with DENV immunity present improved immune responses against ZIKV.


2021 ◽  
Author(s):  
Suhas Sureshchandra ◽  
Sloan A. Lewis ◽  
Brianna Doratt ◽  
Allen Jankeel ◽  
Izabela Ibraim ◽  
...  

mRNA based vaccines for SARS-CoV-2 have shown exceptional clinical efficacy providing robust protection against severe disease. However, our understanding of transcriptional and repertoire changes following full vaccination remains incomplete. We used single-cell RNA sequencing and functional assays to compare humoral and cellular responses to two doses of mRNA vaccine with responses observed in convalescent individuals with asymptomatic disease. Our analyses revealed enrichment of spike-specific B cells, activated CD4 T cells, and robust antigen-specific polyfunctional CD4 T cell responses in all vaccinees. On the other hand, CD8 T cell responses were both weak and variable. Interestingly, clonally expanded CD8 T cells were observed in every vaccinee, as observed following natural infection. TCR gene usage, however, was variable, reflecting the diversity of repertoires and MHC polymorphism in the human population. Natural infection induced expansion of larger CD8 T cell clones occupied distinct clusters, likely due to the recognition of a broader set of viral epitopes presented by the virus not seen in the mRNA vaccine. Our study highlights a coordinated adaptive immune response where early CD4 T cell responses facilitate the development of the B cell response and substantial expansion of effector CD8 T cells, together capable of contributing to future recall responses.


10.1038/ni947 ◽  
2003 ◽  
Vol 4 (8) ◽  
pp. 765-772 ◽  
Author(s):  
Tak W Mak ◽  
Arda Shahinian ◽  
Steve K Yoshinaga ◽  
Andrew Wakeham ◽  
Louis-Martin Boucher ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document